News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,129 Results
Type
Article (8032)
Company Profile (143)
Press Release (479954)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166748)
Career Advice (304)
Deals (25739)
Drug Delivery (7)
Drug Development (52873)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238200)
Policy (17898)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (500)
Accelerated approval (29)
ADA (18)
Adcomms (1)
Allergies (101)
Alliances (33157)
ALS (120)
Alzheimer's disease (997)
Antibody-drug conjugate (ADC) (329)
Approvals (10472)
Artificial intelligence (368)
ASCO (160)
Autoimmune disease (240)
Automation (33)
Bankruptcy (263)
Belgium (4)
Best Places to Work (6957)
BIO (36)
Biologics (42)
BIOSECURE Act (1)
Biosimilars (123)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (24)
Bladder cancer (145)
Brain cancer (35)
Breast cancer (544)
Cancer (4023)
Cardiovascular disease (237)
Career advice (245)
Career pathing (1)
CAR-T (186)
CDC (2)
CDMO (29)
Celiac Disease (3)
Cell therapy (513)
Cervical cancer (36)
Clinical research (48449)
Collaboration (1360)
Commercialization (24)
Compensation (1612)
Complete response letters (36)
COVID-19 (772)
CRISPR (68)
C-suite (856)
Cystic fibrosis (89)
Data (6366)
Denatured (4)
Depression (108)
Dermatology (97)
Diabetes (381)
Diagnostics (4261)
Digital health (41)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (170)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (174)
Earnings (73953)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (237)
Events (88780)
Executive appointments (736)
Eye disease (3)
FDA (12675)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (995)
Gene editing (132)
Generative AI (13)
Gene therapy (352)
GLP-1 (311)
Government (952)
Grass and pollen (2)
Guidances (281)
Healthcare (9391)
Hematology (95)
HIV (56)
Huntington's disease (27)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (81)
Immunology and inflammation (113)
Immuno-oncology (71)
Indications (184)
Infectious disease (979)
Inflammatory bowel disease (141)
Inflation Reduction Act (4)
Influenza (88)
Intellectual property (271)
Interviews (41)
IPO (12398)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (87)
Layoffs (59)
Legal (5195)
Licensing (47)
Liver cancer (47)
Longevity (26)
Lung cancer (577)
Lung diease (8)
Lymphoma (268)
Machine learning (30)
Management (3)
Manufacturing (619)
Marketing (19)
MASH (122)
Medical affairs (2)
Medical device (8714)
Medtech (8903)
Mergers & acquisitions (14457)
Metabolic disorders (769)
mRNA (73)
Multiple sclerosis (116)
Multispecific (3)
NASH (4)
Netherlands (3)
Neurodegenerative disease (242)
Neuropsychiatric disorders (40)
Neuroscience (1944)
Neurotech (2)
NextGen: Class of 2026 (3151)
Non-profit (844)
Obesity (241)
Opinion (10)
Ovarian cancer (181)
Pain (192)
Pancreatic cancer (231)
Parkinson's disease (217)
Partnered (12)
Patents (524)
Patient advocacy (2)
Patient recruitment (548)
Patient selection (45)
Peanut (33)
People (41531)
Peptides (15)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15637)
Phase 2 (21647)
Phase 3 (14616)
Pipeline (8440)
Policy (18)
Postmarket research (1570)
Preclinical (6596)
Press Release (34)
Prostate cancer (208)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (625)
Real estate (3024)
Recruiting (6)
Regenerative medicine (13)
Regulatory (15187)
Reports (23)
Research institute (591)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (110)
Series A (174)
Series B (126)
Service/supplier (5)
Sickle cell disease (65)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2022)
Stem cells (2)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (55)
Tariffs (2)
Vaccines (352)
Venture capital (17)
Weight loss (77)
Wet AMD (3)
Women's health (100)
Date
Today (61)
Last 7 days (424)
Last 30 days (1724)
Last 365 days (19207)
2026 (15729)
2025 (19253)
2024 (22987)
2023 (26539)
2022 (34587)
2021 (37167)
2020 (33470)
2019 (23261)
2018 (17470)
2017 (18769)
2016 (17919)
2015 (24265)
2014 (21679)
2013 (18136)
2012 (20222)
2011 (20443)
2010 (20333)
Location
Africa (232)
Alabama (80)
Alaska (2)
Arizona (321)
Arkansas (12)
Asia (18068)
Australia (2122)
California (12922)
Canada (3367)
China (584)
Colorado (529)
Connecticut (451)
Delaware (227)
Europe (24809)
Florida (1938)
Georgia (409)
Hawaii (3)
Idaho (46)
Illinois (774)
India (60)
Indiana (334)
Iowa (19)
Japan (455)
Kansas (104)
Kentucky (33)
Louisiana (28)
Maine (27)
Maryland (1278)
Massachusetts (8444)
Michigan (322)
Minnesota (600)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (134)
New Hampshire (61)
New Jersey (2843)
New Mexico (12)
New York (3028)
North Carolina (1368)
North Dakota (4)
Northern California (6541)
Ohio (305)
Oklahoma (15)
Oregon (17)
Pennsylvania (2404)
Puerto Rico (24)
Rhode Island (31)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5392)
Tennessee (128)
Texas (2132)
United States (41860)
Utah (392)
Vermont (1)
Virginia (167)
Washington D.C. (39)
Washington State (996)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
488,129 Results for "nanosphere inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Press Releases
Mint Pharmaceuticals Inc. and Bayer Inc. Expand Distribution Partnership in Canada
October 6, 2026
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
Medtronic Completes Separation of MiniMed Group, Inc.
October 15, 2026
·
3 min read
Press Releases
Axogen, Inc. Reports Third Quarter 2026 Financial Results
October 28, 2026
·
19 min read
Job Trends
NanoSphere Opens $2 million Private Placement Offering
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“Nanosphere” or “the Company”) is pleased to announce that it will conclude a private placement of up to CAD$2,000,000, which will incorporate the balance of the financing announced on November 16, 2018 as updated December 17, 2018.
February 12, 2019
·
3 min read
Job Trends
NanoSphere Closes $1.335M First Tranche of Private Placement
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) the biotechnology leader behind the patented NanoSphere Delivery System™, is pleased to announce a first tranche closing of its non-brokered private placement announced November 28, 2018.
December 17, 2018
·
3 min read
Press Releases
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
October 22, 2026
·
18 min read
Business
Game-Changing NanoSphere Products Soon to Disrupt the Oklahoma Cannabis Market
NanoSphere Health Sciences Signs Memorandum of Understanding with 4Evergrn
February 5, 2019
·
5 min read
Job Trends
NanoSphere Announces Revised Terms for Private Placement
NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF) announces revised terms for its non-brokered private placement previously announced on Nov. 16, 2018.
November 28, 2018
·
5 min read
1 of 48,813
Next